Clinical Trial Update: A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease [Phase 2]

View source ↗

Summary

A 12-week Phase 2 safety and pharmacodynamic study of migalastat hydrochloride (AT1001) in participants with Fabry disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Migalastat hydrochloride (migalastat hydrochloride)

Snippet

Sponsor: Amicus Therapeutics | Conditions: Fabry Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-09-07